TITLE

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

AUTHOR(S)
Huhtinen, K.; Suvitie, P.; Hiissa, J.; Junnila, J.; Huvila, J.; Kujari, H.; Setälä, M.; Härkki, P.; Jalkanen, J.; Fraser, J.; Mäkinen, J.; Auranen, A.; Poutanen, M.; Perheentupa, A.
PUB. DATE
April 2009
SOURCE
British Journal of Cancer;4/21/2009, Vol. 100 Issue 8, p1315
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Human epididymal secretory protein E4 (HE4, also known as WAP four-disulphide core domain protein 2) is a new promising biomarker for ovarian cancer but its specificity against ovarian endometriotic cysts is only superficially known. We, thus, analysed serum HE4 concentrations together with a tumour marker CA125 in serum samples of women diagnosed with various types of endometriosis, endometrial cancer or ovarian cancer, and in samples from healthy controls. The mean serum concentration of HE4 was significantly higher in serum samples of patients with both endometrial (99.2 pM, P<0.001) and ovarian (1125.4 pM, P<0.001) cancer but not with ovarian endometriomas (46.0 pM) or other types of endometriosis (45.5 pM) as compared with healthy controls (40.5 pM). The serum CA125 concentrations were elevated in patients with ovarian cancer, advanced endometriosis with peritoneal or deep lesions, or ovarian endometriomas, but not in the patients with endometrial cancer. The microarray results revealed that the mRNA expression of the genes encoding HE4 and CA125 reflected the serum protein concentrations. Taken together, measuring both HE4 and CA125 serum concentrations increases the accuracy of ovarian cancer diagnosis and provides valuable information to discriminate ovarian tumours from ovarian endometriotic cysts.British Journal of Cancer (2009) 100, 1315–1319; doi:10.1038/sj.bjc.6605011 www.bjcancer.com Published online 31 March 2009
ACCESSION #
37591410

 

Related Articles

  • Application of Tumor Markers for the Dualistic Model about Epithelial Ovarian Cancer. ZHANG Shuang-ge // Journal of International Obstetrics & Gynecology;Jun2014, Vol. 41 Issue 3, p285 

    Objective: To explore serum human epididymis protein 4 (HE4), cancer antigen 125 (CA125) for the dualistic model about epithelial ovarian cancer (EOC) application value. Methods: The electrochemical luminescence method to detect serum HE4 and CA125 levels of patients in hospital to be intend to...

  • Ascites and a raised serum Ca 125--confusing combination. Siberstein, Lev B.; Rosenthal, Adam N.; Coppack, Simon W.; Noonan, Kate; Jacobs, Ian J. // Journal of the Royal Society of Medicine;Nov2001, Vol. 94 Issue 11, p581 

    The article discusses the misconceptions in the measurement of serum Cancer Antigen 125 in a woman with ascites. The idea that the serum is a diagnostic marker of an ovarian cancer is perceived to be inappropriate, especially among postmenopausal female with ascites. Apparently, it is suggested...

  • Identification of Five Serum Protein Markers for Detection of Ovarian Cancer by Antibody Arrays. Jiang, Weidong; Huang, Ruochun; Duan, Chaohui; Fu, Liwu; Xi, Yun; Yang, Yuebo; Yang, Wei-Min; Yang, Dongzi; Yang, Dong-Hua; Huang, Ruo-Pan // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Background:Protein and antibody arrays have emerged as a promising technology to study protein expression and protein function in a high-throughput manner. These arrays also represent a new opportunity to profile protein expression levels in cancer patients’ samples and to identify useful...

  • Bilateral Ovarian Fibrothecoma Associated with Ascites, Bilateral Pleural Effusion, and Marked Elevated Serum CA-125. Serges Loué, Védi André; Gbary, Eléonore; Koui, Sylvanus; Akpa, Bédi; Kouassi, Adélaide // Case Reports in Obstetrics & Gynecology;2013, p1 

    Background. The risk of ovarian cancer is increased in the association of ovarian tumor, ascites, and hydrothorax with the significant elevated tumor marker CA-125. However, this association can be observed in a rare clinical and benign pathological entity, that is Demons-Meigs' syndrome....

  • Claudin proteins in ovarian cancer. Birrer, M.J.; Morin, Patrice J. // Disease Markers;2007, Vol. 23 Issue 5/6, p453 

    Members of the claudin family of tight junction proteins have been found altered in several malignancies, including ovarian cancer. Because claudin-3 and -4 are elevated in the vast majority of ovarian tumors, they may represent useful biomarkers for detection and prognosis, as well as ideal...

  • Stage-specific analysis of plasma protein profiles in ovarian cancer: Difference in-gel electrophoresis analysis of pooled clinical samples. Bailey, Mark J.; Shield-Artin, Kristy L.; Oliva, Karen; Ayhan, Mustafa; Reisman, Simone; Rice, Gregory E. // Journal of Carcinogenesis;2012 Special Issue, p1 

    Introduction: Ovarian cancer is the leading cause of death from gynecological cancer. Non-specific symptoms early in disease and the lack of specific biomarkers hinder early diagnosis. Multi-marker blood screening tests have shown promise for improving identification of early stage disease;...

  • Highly elevated serum CA-125 levels in patients with non-malignant gynecological diseases. He, Rong-Huan; Yao, Wei-Miao; Wu, Li-Yan; Mao, Yu-Yan // Archives of Gynecology & Obstetrics;Mar2011, Vol. 283, p107 

    Purposes: To identify patients with highly elevated serum CA-125 levels and analyze their clinical characteristics. Methods: Patients with non-malignant gynecologic disease (NMGDs, n = 41), in whom serum CA-125 levels were over 1,000 IU/ml were retrospectively enrolled in the study. Seventy-one...

  • HE4 in the Differential Diagnosis of a Pelvic Mass: A Case Report. Anastasi, Emanuela; Granato, Teresa; Coppa, Anna; Manganaro, Lucia; Giannini, Giuseppe; Comploj, Sara; Frati, Luigi; Midulla, Cecilia // International Journal of Molecular Sciences;Jan2011, Vol. 12 Issue 1, p627 

    Neoplasms of the ovary present an increasing challenge to the physician. Neoplastic ovarian cysts can resemble endometriomas in ultrasound imaging and need to be carefully considered in the differential diagnosis. We report the case of a woman with a strong family history of hereditary breast...

  • Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Callahan, Gwen; Denison, Stacy R; Phillips, Leslie A; Shridhar, Viji; Smith, David I // Oncogene;1/30/2003, Vol. 22 Issue 4, p590 

    Common fragile sites (CFSs) are regions of profound genomic instability that have been hypothesized to play a role in cancer. The major aim of this study was to locate a fragile region associated with ovarian cancer. Differential display (DD)-PCR analysis comparing normal ovarian epithelial...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics